The class of drugs, called PARP inhibitors, fights against tumors with a specific mutation in the MRE11 gene. Approximately 15 percent of colorectal cancers have microsatellite instability, which is an error in the DNA. A large majority of these tumors have the MRE11 gene mutation, suggesting a broader application of PARP inhibitors.
Researchers found PARP inhibitors were even more effective when there are two copies of the MRE11 gene mutation. They are planning to launch a phase 1 clinical trial to test the utility of PARP inhibitors in colorectal cancer patients with two mutated copies of MRE11.
Read the U-M Health release about PARP inhibitors in colorectal cancer.
Related articles on colorectal cancer:
Office Desk Jobs Double Colon Cancer Risk
Local Washington Health Board Reverses Approval of Colonoscopy Campaign
Coverage of Preventive Services Under New Healthcare Law Causing Confusion
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
